相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
Katherine M. Flegal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Surgical Site Infections and Cost in Obese Patients Undergoing Colorectal Surgery
Elizabeth C. Wick et al.
ARCHIVES OF SURGERY (2011)
Vancomycin: We Can't Get There from Here
Nimish Patel et al.
CLINICAL INFECTIOUS DISEASES (2011)
Successful re-challenge of daptomycin therapy after initial rhabdomyolysis with co-administration of simvastatin
Christopher M. Bland et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2011)
Surgical Site Infections Following Bariatric Surgery in Community Hospitals: A Weighty Concern?
Joshua T. Freeman et al.
OBESITY SURGERY (2011)
High-Dose Daptomycin for Treatment of Complicated Gram-Positive Infections: A Large, Multicenter, Retrospective Study
Ravina Kullar et al.
PHARMACOTHERAPY (2011)
Availability of information for dosing injectable medications in underweight or obese patients
Kimberly A. Jacques et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2010)
Treatment of Meningitis Caused by Vancomycin-Resistant Enterococcus faecium: High-Dose and Combination Daptomycin Therapy
Jennifer Le et al.
ANNALS OF PHARMACOTHERAPY (2010)
Daptomycin Exposure and the Probability of Elevations in the Creatine Phosphokinase Level: Data from a Randomized Trial of Patients with Bacteremia and Endocarditis
Sujata M. Bhavnani et al.
CLINICAL INFECTIOUS DISEASES (2010)
Obesity as a Risk Factor for Nosocomial Infections in Trauma Patients
Pablo E. Serrano et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2010)
Estimation of creatinine clearance in morbidly obese patients
Jasmina A. Demirovic et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2009)
Safety and Clinical Outcomes when Utilizing High-Dose (≥8 mg/kg) Daptomycin Therapy
Pamela A. Moise et al.
ANNALS OF PHARMACOTHERAPY (2009)
Safety of High-Dose Intravenous Daptomycin Treatment: Three-Year Cumulative Experience in a Clinical Program
D. A. Figueroa et al.
CLINICAL INFECTIOUS DISEASES (2009)
Relationship between Initial Vancomycin Concentration-Time Profile and Nephrotoxicity among Hospitalized Patients
Thomas P. Lodise et al.
CLINICAL INFECTIOUS DISEASES (2009)
Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor
Randy O. Odero et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Obesity and Site-Specific Nosocomial Infection Risk in the Intensive Care Unit
Lesly A. Dossett et al.
SURGICAL INFECTIONS (2009)
Cost of bloodstream infections
Meredith Kilgore et al.
AMERICAN JOURNAL OF INFECTION CONTROL (2008)
Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations
Warren E. Rose et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin
T. P. Lodise et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria
D. E. Katz et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin
Burke A. Cunha et al.
HEART & LUNG (2007)
Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin
Manjunath P. Pai et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections -: Efficacy and toxicity
Levita K. Hidayat et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers
Mark Benvenuto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
Vance G. Fowler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent:: Cure with prolonged/high-dose daptomycin without toxicity
BA Cunha et al.
HEART & LUNG (2006)
Morbid obesity is an independent determinant of death among surgical critically ill patients
SA Nasraway et al.
CRITICAL CARE MEDICINE (2006)
The pharmacokinetics of Daptomycin in moderately obese, morbidly obese, and matched Nonobese subjects
BH Dvorchik et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study
H Wisplinghoff et al.
CLINICAL INFECTIOUS DISEASES (2004)
In vivo pharmacodynamic activity of daptomycin
N Safdar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Preoperative risk factors for nasal carriage of Staphylococcus aureus
LA Herwaldt et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2004)
Daptomycin dose-effect relationship against resistant gram-positive organisms
R Cha et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Effects of obesity on pharmacokinetics - Implications for drug therapy
G Cheymol
CLINICAL PHARMACOKINETICS (2000)
In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains
MJ Rybak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
分享论文
